Imugene (ASX: IMU) has been granted patent protection for its Receptor Mimic Technology (RMT) in the United States. [ + ]

The Australian Proteome Analysis Facility, headquartered at Sydney's Macquarie University, is to team up with global life science supplier Qiagen in a AUD$1m research project to develop more efficient ways of removing high-abundance proteins from serum samples. [ + ]

Following the resignation just before Christmas of AusBiotech executive director Tony Coulepis, the industry body will appoint a CEO to replace him. [ + ]

Queensland BioCapital Funds has invested a further $1.9 million in antibiotic-developer Glycoz, bringing its total stake in the company to $2.4 million [ + ]

Chemeq (ASX: CMQ) looks likely to be bailed out of its financial woes by Japanese investor Mizuho International (MZI). But the rescue comes at a price, and Chemeq must meet a string of covenants in order for the deal to continue. [ + ]

Metabolic Pharmaceuticals' CEO Chris Belyea is looking forward to stepping down from the hot seat and focusing on the science and technology aspects of biotechnology. [ + ]

Obesity drug-developer Metabolic (ASX:MBP) announced today that the company is searching for a new CEO and that when an appointment is made, founding CEO Chris Belyea will move into a "scientific and technical" role within the company. [ + ]

The lawsuit issued by Sydney's Ventracor (ASX:VCR) late last year against US artificial heart company Heartware doesn't seem to have dampened enthusiasm for the newcomer's initial public offering. [ + ]

Shares in Visionmed (ASX:VSG) rose 1.3 cents to 4.4 cents today, before relaxing to 4.3 cents, on news that the Perth medical-device company is gearing up to market and distribute its Funhaler asthma spacer device for children in the US. [ + ]

Cytopia (ASX: CYT) has acquired the assets of its US collaborator Myomatrix in a deal worth about US$625,000. [ + ]

Virax (ASX:VHL) has secured $3.25 million of the $4 million it was aiming to raise through a non-renounceable share purchase plan. [ + ]

How do new species evolve and adapt to changes in their environment? The human lifespan is too brief to observe evolution occurring in vivo, while the fossil record is too fragmentary to track species in transit between ancestral and extant life forms. [ + ]

Melbourne meditech company Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) is prepared to take its lead drug for Alzheimer's disease all the way to the market if a major clinical trial in the UK confirms its efficacy. [ + ]

Shares in Sydney anti-viral drug developer Narhex Life Sciences' (ASX:NLS) made a promising debut this morning, listing at 4 cents above their $0.20 issue price. However they failed to maintain momentum, and at time of writing had dropped to $0.19. [ + ]

A Brisbane scientist has discovered deep-sea predators such as swordfish, tuna and sharks warm their eyes and brain to give them superior vision when hunting.